What a two-lane system could look like when the goal is fewer funerals, less chaos, stronger accountability, and faster access to real help.

Executive Summary

Prohibition did not create a drug-free society. It created an unregulated supply chain.

That matters because when the supply chain is unregulated, people do not know dose, purity, contaminants, or strength. They guess. And in a fentanyl-era market, bad guesses kill. That is why harm reduction belongs in any honest reform conversation. The point is not to pretend drugs are safe. The point is to reduce preventable death while building better exits into recovery.[1]

This chapter argues for a two-lane system.

High-risk substances should move through a regulated pharmacy model with standardized products, pharmacist oversight, tight diversion controls, and treatment on demand available through formal referral networks at every purchase.

Lower-risk substances should move through licensed retail channels with age gates, ID checks, security, testing, packaging standards, and clear treatment information at the point of sale.

That is the framework: risk-based drug regulation, not one policy for every substance; accountability, not chaos; addiction treatment, not referral theater.

This is risk-based drug regulation with a regulated pharmacy model for the highest-risk lane and treatment on demand built into the off-ramp.

The Policy Problem This Chapter Solves

Part 9 already made the case for risk-based drug regulation instead of a single rule for every substance.

Part 10 made the accountability point clearly: regulation does not eliminate enforcement. It changes what gets enforced.

Part 7 argued that if treatment funding is not protected, it gets raided, delayed, or turned into campaign talking points.

This chapter answers the next practical question.

What does the highest-risk lane actually look like if the goal is to build something that could pass?

The answer is not open retail. The answer is a pharmacy-based access model for adults already using high-risk substances, plus immediate linked care that is real, immediate, and measured.

Why a Two-Lane System Is More Rational

The public is right to reject one-size-fits-all drug policy reform.

Caffeine is not fentanyl. Cannabis is not methamphetamine. Psilocybin is not heroin. Policy loses credibility when it refuses to distinguish between categories of risk. That is why risk-based drug regulation is the only serious framework. It matches the channel to the danger.

A workable two-lane model would look like this:

High-risk lane

• Dispensed through a regulated pharmacy model
• Restricted to adults with verified high-risk use or substance use disorder
• Small quantities, standardized formulations, tight inventory controls
• Every transaction includes immediate treatment linkage through a linked care network
• Strong diversion penalties and public reporting

Lower-risk lane

• Sold through licensed dispensaries or similarly controlled retail outlets
• Adults only, with ID verification and security requirements
• Testing, labeling, packaging, and purchase limits
• Treatment information and referral access at every point of sale
• Continued enforcement against unlicensed sales, impaired driving, violence, and sales to minors

That is not softness. That is channel discipline.

In practical terms, the lower-risk lane would look closer to a heavily regulated cannabis model. The high-risk lane would look closer to a medical access model with compliance controls and clinical touchpoints. That is a far more realistic form of drug policy reform than pretending every substance belongs on the same shelf.

The High-Risk Lane: The Regulated Pharmacy Model

A regulated pharmacy model is not designed for curiosity, experimentation, or market expansion.

It is designed for one brutal reality: people are already using high-risk substances, and the current street market is killing them.

So the first job is survival.

The second job is stabilization.

The third job is making immediate treatment access easier than it is now.

For this lane to stay politically viable, eligibility has to be narrow and explicit:

• Adults only, ideally 21 and over
• Documented high-risk use, opioid use disorder, or repeated overdose exposure
• Priority for people with prior overdose, repeated emergency encounters, or clear evidence of dangerous street-market dependence
• No first-use access
• No general retail model for the highest-risk products

This model works because pharmacies already operate inside a compliance culture. They know inventory controls. They know audit trails. They know licensing risk. They know documentation standards. They know how to handle privacy rules, secure storage, and chain of custody.[2][3]

That does not mean every community pharmacy becomes a high-risk site. It means selected licensed sites operate under a specialized endorsement with stricter rules, tighter reporting, and direct linkage to hospitals and addiction treatment providers.

What the Pharmacy Would Actually Do

This is where critics usually imagine chaos. It does not have to be chaos.

The high-risk lane should require:

• Verified identity at every transaction
• Standardized dose forms instead of street variability
• Limited quantities with frequent touchpoints
• Real-time inventory reconciliation
• Tamper-resistant packaging and serialized tracking
• Mandatory review of recent pickup history
• Mandatory treatment on demand offer at every purchase
• Immediate referral pathways into assessment, MOUD, residential care, PHP, IOP, or outpatient care

Injectable or ultra-high-risk formulations should not be normal take-home products. Those formats belong in specialist settings, supervised services, or tightly limited clinical environments if they are allowed at all.

That kind of boundary matters. This lane survives politically only if the public can see the restraints.

Treatment on Demand Has to Mean Treatment Now

This is the part most systems fake.

They call a referral a treatment plan.

It is not.

If somebody says yes to help, the system should not answer with a brochure, a voicemail, a six-week waitlist, or an insurance denial. The person has to be connected immediately to a real intake pathway. San Francisco’s Treatment on Demand Act is useful here because it requires the city to maintain publicly funded treatment capacity and report on demand and wait times.[4]

A passable state model should require every high-risk dispensing site to be formally linked to licensed providers that can offer:

• Same-day telehealth assessment when in-person intake is not immediately available
• Same-day or next-day entry into outpatient care when clinically appropriate
• Rapid placement pathways for inpatient or residential treatment
• Direct scheduling into PHP and IOP
• Warm handoffs instead of “here’s a number, good luck”

That is the promise in plain English: when the person asks for help, the system moves.

This also has to be blind to status. Access cannot hinge on whether someone has private insurance, Medicaid, no insurance, stable housing, or no housing. That promise only means something if the front door opens for the addict, not just for the insured patient with paperwork in order.

Medications for Opioid Use Disorder Are the Default Exit Ramp

For opioid users, the most important bridge out of chaos is not a speech. It is medications for opioid use disorder.

CDC says medication treatment for opioid use disorder is associated with reduced overdose risk and overall mortality, and it tells clinicians to offer or arrange evidence-based treatment with FDA-approved medications.[5] NIDA makes the same point and notes that fewer than one in five people with opioid use disorder receive these medications.[6] In other words, medications for opioid use disorder are not niche tools. They are core overdose-prevention medicine.

That gap is insane.

It means the country is still acting like access to MOUD is optional when the evidence says it saves lives.

A serious model would treat MOUD as the default stabilization pathway, not the backup plan. That means:

• Buprenorphine access should be fast and routine
• Methadone linkage should be immediate where clinically appropriate
• Naltrexone should remain available for the patients who want it and fit it
• Pharmacies should coordinate directly with OTPs, hospitals, and office-based prescribers
• Refusal of counseling should not block medication access when medication is otherwise appropriate under federal rules[7]

The MAT Act removed the old federal waiver requirement for buprenorphine prescribing, and the revised Part 8 rules expanded flexibility inside opioid treatment programs.[8][9] The policy direction is already moving toward access. The mistake would be refusing to build a front-end system that actually uses it.

This is also where hospitals should stop standing on the sidelines. Starting care earlier and linking faster is cheaper than endless overdose reversals, admissions, and discharge loops. Research on emergency-department-initiated buprenorphine found it improved treatment engagement and was cost-effective compared with referral alone.[10][11]

That is one reason MOUD should be central to this model. Medications for opioid use disorder are not just clinically serious. They are fiscally serious.

Where Pharmacy Safe Supply Fits

Pharmacy safe supply is the phrase that makes this debate combustible, so it needs precision.

Pharmacy safe supply should not mean an ideology, a free-for-all, or a denial that diversion risk exists.

It should mean a narrowly governed option for people already at high risk from the toxic illegal market, delivered through tight audit trails, limited quantities, standardized products, and constant measurement.

Health Canada defines safer supply as prescribed medications used as a safer alternative to the toxic illegal drug supply for people at high risk of overdose.[12] The literature is mixed enough to demand discipline. A 2024 scoping review found generally beneficial client-reported outcomes but also emphasized the need for stronger evidence.[13] A 2024 JAMA Internal Medicine study on British Columbia’s safer opioid supply policy found increased prescribing and claimant rates but also higher opioid-poisoning hospitalizations, with no statistically significant change in deaths over the study period.[14] A 2024 JAMA Network Open qualitative study found diversion concerns were real and often tied to unmet need, withdrawal management, poverty, theft, and social vulnerability.[15]

So the adult answer is straightforward:

Pharmacy safe supply belongs inside pilot programs, strict oversight, independent evaluation, and hard course correction when the data says something is off.

That is how drug policy reform avoids becoming faith-based policy.

The Lower-Risk Lane Still Needs Real Rules

Lower-risk does not mean harmless.

It means the access channel can be broader because the acute risk profile is lower and retail controls can do more of the safety work.

This lane should look more like a licensed dispensary model with:

• Adult-only access
• Security plans
• ID verification
• Purchase limits
• Testing and contaminant standards
• Accurate labeling
• Child-resistant packaging where relevant
• Staff training on treatment information and impairment warnings

Treatment information should be mandatory even in the lower-risk lane. Washington State’s description of SBIRT is useful here because it frames screening, brief intervention, and referral to treatment as an evidence-based model for identifying risky use and moving people toward help earlier.[16]

You do not need every dispensary worker to be a clinician.

You do need every point of sale to make the next step visible.

That keeps harm reduction and addiction treatment in the picture without pretending every customer is the same.

Funding Has to Reward Outcomes, Not Cycling

This is where most reform plans fall apart.

They say treatment and assume the word itself solves the incentive problem.

It does not.

If providers get paid mainly for volume, the system will produce churn. Intake, discharge, relapse, repeat. Bill, recycle, repeat. That is not recovery. That is a business model.

A passable framework should combine base funding with performance-based reimbursement:

• Base funding guarantees immediate treatment capacity
• Performance payments reward retention, reduced overdose, reduced ER use, improved employment, and reduced reincarceration
• Risk adjustment protects providers that take harder cases
• Independent evaluation prevents self-congratulatory nonsense

SAMHSA’s work on value-based payment for substance use disorder services points directly toward this kind of structure.[17] CMS’s Value in Treatment demonstration did the same at the federal level for opioid use disorder treatment, with explicit goals around access, health outcomes, and lower expenditures.[18] Medicaid Section 1115 SUD demonstrations already give states a real pathway to test models that improve access and measure results.[19]

Drug policy reform becomes more politically viable when it can say this plainly: we are not just spending more money. We are buying fewer funerals, fewer overdoses, fewer revolving-door ER visits, and more durable recovery.

And yes, that means longitudinal measurement.

If a program claims success, it should have to show six-month, twelve-month, and twenty-four-month outcomes where possible:

• retention in addiction treatment
• continued use of medications for opioid use disorder where appropriate
• overdose recurrence
• emergency department utilization
• housing stability
• employment or return-to-work indicators
• criminal legal system contact

That is how you stop treatment cycling from becoming the hidden subsidy of a broken system.

Why This Model Could Actually Pass

A serious proposal has to survive normal political attacks.

This one can, because it does not ask the public to ignore risk. It asks the public to govern it better.

Why it is more passable than sweeping rhetoric:

1. It separates high-risk from lower-risk substances
2. It keeps real enforcement for unlicensed sales, diversion, violence, fraud, and impaired driving
3. It uses a regulated pharmacy model only for the highest-risk lane
4. It makes treatment on demand mandatory instead of optional
5. It aligns hospitals, insurers, treatment providers, and public health agencies around measurable outcomes
6. It can start as a state pilot through demonstration authority instead of a national overnight rewrite

It also fits the logic of earlier parts of this series.

Part 11 argued that prevention has to be evidence-based, not fear propaganda.

Part 12 showed how deadly the release window is when continuity of care fails.

Part 13 made the case that addiction often rides on trauma, instability, housing collapse, and untreated mental health problems.

A serious system connects those dots. It does not isolate the drug and ignore the human being.

The Bottom Line

The current system already rations care, protects chaos, and leaves the dead to make the argument.

A regulated pharmacy model will not create a perfect world. Risk-based drug regulation will not eliminate addiction. Treatment on demand will not save every person. Medications for opioid use disorder will not fit every case. Drug policy reform will still require enforcement, prevention, housing support, overdose prevention, and accountability.

But this is the right comparison:

Not utopia versus reform.

Reality versus reform.

And reality is an illegal market, inconsistent potency, contamination, overdose, untreated addiction, fake referrals, and endless moral theater.

A better system would do three things at once:

• replace chaos with standards
• replace delays with treatment on demand
• replace slogans with measurable outcomes

That is the strongest case for a regulated pharmacy model.

Not that it is perfect.

That it is more honest than prohibition, more disciplined than open-ended rhetoric, and more likely to keep people alive long enough to choose recovery.

If you or someone you love needs help right now, SAMHSA’s National Helpline is available 24/7 at 1-800-662-HELP (4357).[20]

If you want to follow the full series as it publishes, visit the blog.
If you prefer audio conversations on recovery, reentry, and purpose, check the podcast page.
And if you want the longer story behind why I write about this, start here.

Frequently Asked Questions

Is the regulated pharmacy model the same as “legal heroin” or “retail fentanyl”?

No. The regulated pharmacy model in this chapter is not open retail for the general public. It is a tightly restricted medical-access channel for adults already using high-risk substances and already exposed to overdose risk. The point is not to normalize dangerous drug use. The point is to replace street unpredictability with standardized products, pharmacist oversight, diversion control, and a standing off-ramp into treatment on demand.

Would treatment have to happen inside the pharmacy?

No. The pharmacy does not need to become a rehab center. What it does need is a formal, working connection to licensed providers that can take people immediately or by the next day. That means real intake pathways into inpatient care, residential treatment, PHP, IOP, outpatient care, and medications for opioid use disorder. The key is not where the treatment happens. The key is whether the person can actually get in without delay when they say yes.

What does treatment on demand mean in practice?

Treatment on demand means the system moves when the person asks for help. It does not mean handing someone a phone number and hoping they call later. A serious model would require same-day assessment when possible, same-day telehealth intake when needed, and warm handoffs into the correct level of care instead of referral theater. San Francisco’s Treatment on Demand framework is useful because it treats capacity and wait times as things government should track and report, not ignore.[4]

Would this replace medications for opioid use disorder?

No. It should strengthen them. Medications for opioid use disorder should be the default stabilization option for opioid users who want to reduce overdose risk and regain control. That includes faster access to buprenorphine, methadone where appropriate, and other evidence-based options. CDC and NIDA are both clear that medications for opioid use disorder reduce overdose risk and improve outcomes.[5][6] This model works best when the regulated pharmacy model functions as a bridge into care, not as a substitute for real addiction treatment.

What happens with lower-risk substances?

Lower-risk substances should not be handled the same way as the highest-risk lane. That is the whole point of risk-based drug regulation. Lower-risk products can move through licensed dispensaries or similarly regulated retail settings with adult-only access, ID verification, security, testing, labeling, packaging rules, and clear treatment information at the point of sale. That is still drug policy reform, but it is drug policy reform built around risk tiers instead of one blunt rule for everything.

Won’t a regulated pharmacy model increase drug use?

That is the wrong comparison. The real comparison is not this model versus a fantasy world with zero drug use. The real comparison is this model versus the current reality of fentanyl contamination, inconsistent potency, contamination, overdose, and fake access to care. This framework is not built for first-time initiation. It is built for people already exposed to high-risk use. Its first goal is harm reduction and overdose prevention. Its second goal is making recovery easier to reach.

How would diversion be controlled?

Diversion control has to be built in from day one. That means limited quantities, frequent touchpoints, verified identity, real-time inventory tracking, audit trails, license sanctions, and strong enforcement against unlicensed resale. It also means piloting, measuring, and correcting problems instead of pretending they do not exist. The safer-supply debate has already shown that diversion concerns are real, which is exactly why this model has to be tighter than activist slogans and tougher than street-market chaos.[15]

Why not just expand addiction treatment under prohibition?

Because addiction treatment alone does not fix a toxic supply chain. Even a better treatment system still leaves people exposed to contaminated street drugs if the illegal market stays in control. Prohibition and addiction treatment are not interchangeable policy tools. One governs the supply channel. The other helps people recover. A serious framework needs both. That is why this chapter argues for drug policy reform that pairs a regulated pharmacy model with treatment on demand, rather than pretending one side of the problem can solve the whole thing.

Why would hospitals and insurers support this?

Because the current system is expensive and wasteful. Repeated overdoses, emergency department visits, inpatient admissions, discharges without continuity, and rapid relapse are all costly. Earlier treatment linkage and faster access to medications for opioid use disorder are cheaper than endless crisis care. Research on emergency-department-initiated buprenorphine found better treatment engagement and favorable cost-effectiveness compared with referral alone.[10][11] For hospitals and insurers, this is not just social policy. It is operational logic.

Could this actually pass politically?

It has a far better chance than broad “legalize everything” rhetoric because it accepts risk instead of denying it. This framework is narrower, more accountable, and easier to explain to the public. It separates high-risk from lower-risk substances. It keeps penalties for unlicensed sales, diversion, violence, fraud, and impaired driving. It requires public reporting, outcome tracking, and real treatment access. In other words, it treats drug policy reform as governance, not as a slogan.

References

[1] CDC National Center for Health Statistics. U.S. Overdose Deaths Decrease Almost 27% in 2024. https://www.cdc.gov/nchs/pressroom/releases/20250514.html

[2] U.S. Department of Health and Human Services. Fact Sheet: 42 CFR Part 2 Final Rule. https://www.hhs.gov/hipaa/for-professionals/regulatory-initiatives/fact-sheet-42-cfr-part-2-final-rule/index.html

[3] Federal Register. Confidentiality of Substance Use Disorder (SUD) Patient Records. https://www.federalregister.gov/documents/2024/02/16/2024-02544/confidentiality-of-substance-use-disorder-sud-patient-records

[4] City and County of San Francisco. Treatment on Demand Act. https://www.sf.gov/resource–2022–treatment-demand-act

[5] CDC. Opioid Use Disorder: Treating. https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html

[6] National Institute on Drug Abuse. Medications for Opioid Use Disorder. https://nida.nih.gov/research-topics/medications-opioid-use-disorder

[7] SAMHSA. 42 CFR Part 8 Final Rule Frequently Asked Questions. https://www.samhsa.gov/medications-substance-use-disorders/statutes-regulations-guidelines/42-cfr-part-8/faqs

[8] SAMHSA. Waiver Elimination (MAT Act). https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act

[9] SAMHSA. Substance Use Disorders – Statutes, Regulations, and Guidelines. https://www.samhsa.gov/medications-substance-use-disorders/statutes-regulations-guidelines

[10] D’Onofrio G, et al. Emergency Department-Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/25919527/

[11] Busch SH, et al. Cost-effectiveness of Emergency Department-Initiated Treatment for Opioid Dependence. https://pubmed.ncbi.nlm.nih.gov/28815789/

[12] Health Canada. Safer supply: Prescribed medications as a safer alternative to toxic illegal drugs. https://www.canada.ca/en/health-canada/services/opioids/responding-canada-opioid-crisis/safer-supply.html

[13] Ledlie S, et al. Prescribed safer opioid supply: A scoping review of the evidence. https://pubmed.ncbi.nlm.nih.gov/38335867/

[14] Nguyen HV, et al. British Columbia’s Safer Opioid Supply Policy and Opioid Outcomes. https://pubmed.ncbi.nlm.nih.gov/38227344/

[15] Olding M, et al. Perspectives on Diversion of Medications From Safer Opioid Supply Programs. https://pubmed.ncbi.nlm.nih.gov/39693066/

[16] Washington State Health Care Authority. Substance use treatment: Screening, Brief Intervention, and Referral to Treatment (SBIRT). https://www.hca.wa.gov/billers-providers-partners/program-information-providers/substance-use-treatment

[17] SAMHSA Library. Exploring Value-Based Payment for Substance Use Disorder Services in the United States. https://library.samhsa.gov/product/exploring-value-based-payment-substance-use-disorder-services-united-states/pep23-06-07-001

[18] CMS Innovation Center. Value in Opioid Use Disorder Treatment Demonstration Program. https://www.cms.gov/priorities/innovation/innovation-models/value-in-treatment-demonstration

[19] Medicaid.gov. Substance Use Disorder Section 1115 Demonstration Opportunity. https://www.medicaid.gov/medicaid/section-1115-demonstrations/substance-use-disorder-section-1115-demonstration-opportunity

[20] SAMHSA. National Helpline. https://www.samhsa.gov/find-help/national-helpline